Showing results (511-520 of 1,361) with videos related to
Sort By:
Pageof 137
Drugs Under Experimental and Clinical Research|January 1, 1994
L-propionyl carnitine protects erythrocytes and low density lipoproteins against peroxidationA Bertelli, A Conte, G RoncaDrugs Under Experimental and Clinical Research|January 1, 1994
Dextrorphan and dextromethorphan: comparative antitussive effects on guinea pigsP C Braga, A Fossati, M G Vimercati, et al.Drugs Under Experimental and Clinical Research|January 1, 1991
Treatment of chronic idiopathic urticaria with topical preparations: controlled study of oxatomide gel versus dechlorpheniramine creamF Locci, G S Del GiaccoDrugs Under Experimental and Clinical Research|January 1, 1991
Effects of cefonicid on platelet aggregationM Cazzola, G Santangelo, G Paizis, et al.Drugs Under Experimental and Clinical Research|January 1, 1990
Effects of the optical isomers of a novel 5-HT2 antagonist and (-)-Bay K 8644 on spontaneous mechanical activity in rat portal veinsE O Mikkelsen, T J NielsenDrugs Under Experimental and Clinical Research|September 16, 2004
EPR evaluation of the antiradical activity of wines containing high concentrations of resveratrolA Bertelli, M Falchi, R Lo Scalzo, et al.Drugs Under Experimental and Clinical Research|July 22, 2005
Evaluation of carnitine, acetylcarnitine and isovalerylcarnitine on immune function and apoptosisF Ferrara, A Bertelli, M FalchiDrugs Under Experimental and Clinical Research|July 22, 2005
Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteersM M Cainazzo, D Pinetti, G Savino, et al.Drugs Under Experimental and Clinical Research|January 1, 1992
Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placeboV Coto, L D'Alessandro, G Grattarola, et al.Drugs Under Experimental and Clinical Research|January 1, 1992
Cellular electrophysiological effects of platelet-activating factor (PAF) and its antagonist BN 52021 in cardiac preparationsV Kecskemeti, P BraquetPageof 137